Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received a consensus recommendation of “Hold” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $4.93.

A number of research firms have recently commented on SGMO. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective (up previously from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th. Finally, StockNews.com assumed coverage on Sangamo Therapeutics in a research report on Tuesday, February 13th. They set a “sell” rating for the company.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $0.51 on Tuesday. Sangamo Therapeutics has a 52-week low of $0.29 and a 52-week high of $1.78. The company has a market cap of $91.26 million, a PE ratio of -0.35 and a beta of 1.39. The business has a fifty day moving average of $0.81 and a 200 day moving average of $0.59.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). The firm had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. As a group, research analysts anticipate that Sangamo Therapeutics will post -0.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Miracle Mile Advisors LLC purchased a new position in Sangamo Therapeutics in the 3rd quarter valued at $25,000. Vanguard Personalized Indexing Management LLC acquired a new position in Sangamo Therapeutics during the third quarter worth about $26,000. Mackenzie Financial Corp grew its stake in Sangamo Therapeutics by 72.4% during the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 31,003 shares in the last quarter. SG Americas Securities LLC raised its holdings in Sangamo Therapeutics by 255.2% in the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 63,612 shares during the last quarter. Finally, Golden State Equity Partners boosted its stake in Sangamo Therapeutics by 22.5% during the third quarter. Golden State Equity Partners now owns 166,265 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 30,500 shares during the last quarter. Hedge funds and other institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.